Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion
I'm PortAI, I can summarize articles.
Fosun Pharma Industrial is acquiring a majority stake in an Alzheimer's drug developer for RMB1.27 billion. The deal includes purchasing 8.6667% equity from Shiyin Investment and Shibirun for RMB143 million, and subscribing to new capital for a 46.3504% stake. A special purpose vehicle will be formed with a 51% stake held by Fosun Pharma. The acquisition aims to enhance Fosun Pharma's market position and advance Alzheimer's treatment development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments